Thyroidal effect of metformin treatment in patients with polycystic ovary syndrome

Mario Rotondi, Carlo Cappelli, Flavia Magri, Roberta Botta, Rosa Dionisio, Carmelo Iacobello, Pasquale De Cata, Rossella E. Nappi, Maurizio Castellano, Luca Chiovato

Research output: Contribution to journalArticle

39 Citations (Scopus)

Abstract

Objective Metformin is widely used for the treatment of type 2 diabetes. Growing evidence supports the beneficial effects of metformin also in patients with polycystic ovary syndrome (PCOS). It was recently reported that metformin has a TSH-lowering effect in hypothyroid patients with diabetes being treated with metformin. Design Aim of this study was to evaluate the effect of metformin treatment on the thyroid hormone profile in patients with PCOS. Patients and measurements Thirty-three patients with PCOS were specifically selected for being either treated with levothyroxine for a previous diagnosis of hypothyroidism (n = 7), untreated subclinically hypothyroid (n = 2) or euthyroid without levothyroxine treatment (n = 24) before the starting of metformin. The serum levels of TSH and FT 4 were measured before and after a 4-month period of metformin therapy. Results Thyroid function parameters did not change after starting metformin therapy in euthyroid patients with PCOS. In the 9 hypothyroid patients with PCOS, the basal median serum levels of TSH (3·2 mIU/l, range = 0·4-7·1 mIU/l) significantly (P <0·05) decreased after a 4-month course of metformin treatment (1·7 mIU/l, range = 0·5-5·2 mIU/l). No significant change in the serum levels of FT4 was observed in these patients. The TSH-lowering effect of metformin was not related to the administered dose of the drug, which was similar in euthyroid as compared with hypothyroid patients with PCOS (1406 ± 589 vs 1322 ± 402 mg/day, respectively; NS). Conclusions These results indicate that metformin treatment has a TSH-lowering effect in hypothyroid patients with PCOS, both treated with l-thyroxine and untreated.

Original languageEnglish
Pages (from-to)378-381
Number of pages4
JournalClinical Endocrinology
Volume75
Issue number3
DOIs
Publication statusPublished - Sep 2011

Fingerprint

Polycystic Ovary Syndrome
Metformin
Thyroxine
Therapeutics
Serum
Hypothyroidism
Thyroid Hormones
Type 2 Diabetes Mellitus
Thyroid Gland

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism

Cite this

Thyroidal effect of metformin treatment in patients with polycystic ovary syndrome. / Rotondi, Mario; Cappelli, Carlo; Magri, Flavia; Botta, Roberta; Dionisio, Rosa; Iacobello, Carmelo; De Cata, Pasquale; Nappi, Rossella E.; Castellano, Maurizio; Chiovato, Luca.

In: Clinical Endocrinology, Vol. 75, No. 3, 09.2011, p. 378-381.

Research output: Contribution to journalArticle

Rotondi, Mario ; Cappelli, Carlo ; Magri, Flavia ; Botta, Roberta ; Dionisio, Rosa ; Iacobello, Carmelo ; De Cata, Pasquale ; Nappi, Rossella E. ; Castellano, Maurizio ; Chiovato, Luca. / Thyroidal effect of metformin treatment in patients with polycystic ovary syndrome. In: Clinical Endocrinology. 2011 ; Vol. 75, No. 3. pp. 378-381.
@article{84ff4badc21a4d109fbc4f3315a2d483,
title = "Thyroidal effect of metformin treatment in patients with polycystic ovary syndrome",
abstract = "Objective Metformin is widely used for the treatment of type 2 diabetes. Growing evidence supports the beneficial effects of metformin also in patients with polycystic ovary syndrome (PCOS). It was recently reported that metformin has a TSH-lowering effect in hypothyroid patients with diabetes being treated with metformin. Design Aim of this study was to evaluate the effect of metformin treatment on the thyroid hormone profile in patients with PCOS. Patients and measurements Thirty-three patients with PCOS were specifically selected for being either treated with levothyroxine for a previous diagnosis of hypothyroidism (n = 7), untreated subclinically hypothyroid (n = 2) or euthyroid without levothyroxine treatment (n = 24) before the starting of metformin. The serum levels of TSH and FT 4 were measured before and after a 4-month period of metformin therapy. Results Thyroid function parameters did not change after starting metformin therapy in euthyroid patients with PCOS. In the 9 hypothyroid patients with PCOS, the basal median serum levels of TSH (3·2 mIU/l, range = 0·4-7·1 mIU/l) significantly (P <0·05) decreased after a 4-month course of metformin treatment (1·7 mIU/l, range = 0·5-5·2 mIU/l). No significant change in the serum levels of FT4 was observed in these patients. The TSH-lowering effect of metformin was not related to the administered dose of the drug, which was similar in euthyroid as compared with hypothyroid patients with PCOS (1406 ± 589 vs 1322 ± 402 mg/day, respectively; NS). Conclusions These results indicate that metformin treatment has a TSH-lowering effect in hypothyroid patients with PCOS, both treated with l-thyroxine and untreated.",
author = "Mario Rotondi and Carlo Cappelli and Flavia Magri and Roberta Botta and Rosa Dionisio and Carmelo Iacobello and {De Cata}, Pasquale and Nappi, {Rossella E.} and Maurizio Castellano and Luca Chiovato",
year = "2011",
month = "9",
doi = "10.1111/j.1365-2265.2011.04042.x",
language = "English",
volume = "75",
pages = "378--381",
journal = "Clinical Endocrinology",
issn = "0300-0664",
publisher = "Wiley-Blackwell",
number = "3",

}

TY - JOUR

T1 - Thyroidal effect of metformin treatment in patients with polycystic ovary syndrome

AU - Rotondi, Mario

AU - Cappelli, Carlo

AU - Magri, Flavia

AU - Botta, Roberta

AU - Dionisio, Rosa

AU - Iacobello, Carmelo

AU - De Cata, Pasquale

AU - Nappi, Rossella E.

AU - Castellano, Maurizio

AU - Chiovato, Luca

PY - 2011/9

Y1 - 2011/9

N2 - Objective Metformin is widely used for the treatment of type 2 diabetes. Growing evidence supports the beneficial effects of metformin also in patients with polycystic ovary syndrome (PCOS). It was recently reported that metformin has a TSH-lowering effect in hypothyroid patients with diabetes being treated with metformin. Design Aim of this study was to evaluate the effect of metformin treatment on the thyroid hormone profile in patients with PCOS. Patients and measurements Thirty-three patients with PCOS were specifically selected for being either treated with levothyroxine for a previous diagnosis of hypothyroidism (n = 7), untreated subclinically hypothyroid (n = 2) or euthyroid without levothyroxine treatment (n = 24) before the starting of metformin. The serum levels of TSH and FT 4 were measured before and after a 4-month period of metformin therapy. Results Thyroid function parameters did not change after starting metformin therapy in euthyroid patients with PCOS. In the 9 hypothyroid patients with PCOS, the basal median serum levels of TSH (3·2 mIU/l, range = 0·4-7·1 mIU/l) significantly (P <0·05) decreased after a 4-month course of metformin treatment (1·7 mIU/l, range = 0·5-5·2 mIU/l). No significant change in the serum levels of FT4 was observed in these patients. The TSH-lowering effect of metformin was not related to the administered dose of the drug, which was similar in euthyroid as compared with hypothyroid patients with PCOS (1406 ± 589 vs 1322 ± 402 mg/day, respectively; NS). Conclusions These results indicate that metformin treatment has a TSH-lowering effect in hypothyroid patients with PCOS, both treated with l-thyroxine and untreated.

AB - Objective Metformin is widely used for the treatment of type 2 diabetes. Growing evidence supports the beneficial effects of metformin also in patients with polycystic ovary syndrome (PCOS). It was recently reported that metformin has a TSH-lowering effect in hypothyroid patients with diabetes being treated with metformin. Design Aim of this study was to evaluate the effect of metformin treatment on the thyroid hormone profile in patients with PCOS. Patients and measurements Thirty-three patients with PCOS were specifically selected for being either treated with levothyroxine for a previous diagnosis of hypothyroidism (n = 7), untreated subclinically hypothyroid (n = 2) or euthyroid without levothyroxine treatment (n = 24) before the starting of metformin. The serum levels of TSH and FT 4 were measured before and after a 4-month period of metformin therapy. Results Thyroid function parameters did not change after starting metformin therapy in euthyroid patients with PCOS. In the 9 hypothyroid patients with PCOS, the basal median serum levels of TSH (3·2 mIU/l, range = 0·4-7·1 mIU/l) significantly (P <0·05) decreased after a 4-month course of metformin treatment (1·7 mIU/l, range = 0·5-5·2 mIU/l). No significant change in the serum levels of FT4 was observed in these patients. The TSH-lowering effect of metformin was not related to the administered dose of the drug, which was similar in euthyroid as compared with hypothyroid patients with PCOS (1406 ± 589 vs 1322 ± 402 mg/day, respectively; NS). Conclusions These results indicate that metformin treatment has a TSH-lowering effect in hypothyroid patients with PCOS, both treated with l-thyroxine and untreated.

UR - http://www.scopus.com/inward/record.url?scp=79961218545&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79961218545&partnerID=8YFLogxK

U2 - 10.1111/j.1365-2265.2011.04042.x

DO - 10.1111/j.1365-2265.2011.04042.x

M3 - Article

C2 - 21521311

AN - SCOPUS:79961218545

VL - 75

SP - 378

EP - 381

JO - Clinical Endocrinology

JF - Clinical Endocrinology

SN - 0300-0664

IS - 3

ER -